Fig. 3

miR-184 delays onset of metastases (mets) in distant organs and prolongs survival. a Growth rate of tumours after injection of MDA-MB-231 into the mammary fat pad in NOD/SCID mice (n = 10 per group) constitutively overexpressing miR-184, let-7a or negative control. b Representative images of micrometastases in the lung and percentage of NOD/SCID mice (n = 10) with 0, 1–20 or 21–40 metastatic lesions in the lung. c Pancreas of control and miR-184 cohorts and percentage of NOD/SCID mice (n = 10) with 0, 1–20 or 21–30 metastatic lesions in the pancreas. The t test was performed; *p <0.05 indicates significant difference in the number of micrometastases in miR-184 cohort compared to control cohort. Scale bar = 200 μM. NS not significant